The global liquid biopsy market is anticipated to see a significant increase in value; industry projections place its value at USD 10,938.6 million by 2033. This significant expansion is anticipated to be driven by a robust Compound Annual Growth Rate (CAGR) of 21.7% over the ensuing ten years (2023–2033).
Liquid biopsy is a revolutionary non-invasive real-time cancer tracking and detection technology that evaluates tumor-related biomarkers in biofluids such as blood, urine, and cerebrospinal fluid. As our understanding of cancer biology and molecular diagnostics advances, liquid biopsy technologies are revolutionizing cancer care by offering tailored treatment selection, monitoring treatment response, and early detection.
The gold standard for identifying the kind and stage of cancer at this time is tumor tissue. In order to expand its potential applications in the future, significant players are working to remove the current barriers to its use. Numerous studies have also demonstrated the viability of liquid biopsy procedures for determining the genetic profiles of cancer patients. In order to monitor the course of treatment and spot any early warning indicators of therapeutic resistance, the studies attentively consider the reactions.
Elevate Knowledge: Obtain Your Report Sample:
https://www.futuremarketinsights.com/reports/sample/rep-gb-1396
The need for more individualized treatment choices has driven the usage of liquid biopsies in recent years. Liquid biopsy is becoming more and more popular since it is affordable and accessible in many labs, especially in developing nations. For example, liquid biopsy tests are available at a number of labs in
“Key players are bringing cost reductions in liquid biopsy tests and partnering with local product distributors to strengthen their network base in target markets. Currently, a trend toward emerging economies has been spotted, as cancer cases are particularly on the rise, and a large population base provides significant opportunities in these markets,” says an FMI analyst.
Key Takeaways from the Liquid Biopsy Market Report
- The North America liquid biopsy market is expected to account for a leading share of 50.84%. The United States is predicted to account for 43.8%, enjoying a dominant share in the global and regional markets.
- The Europe market is anticipated to acquire a market share of 19.6% in 2023. Germany holds a prominent share in the region. In 2023, the country is predicted to amass a total of 6.6% share in the global market.
- In Europe, the United Kingdom is predicted to expand at a robust CAGR of 26.4% through 2033.
- In Asia Pacific, China and India display a remarkable percentage of growth, i.e., 29.7% and 24.4%, respectively, through 2033.
- CTC (Circulating Tumor Cells) is projected to obtain a significant market share of 56.9% by biomarker type in 2023.
- By sample type, blood sample type holds prominence in the liquid biopsy market.
Customization Available:
https://www.futuremarketinsights.com/customization-available/REP-GB-1396
Key Developments by Liquid Biopsy Market Players
- QIAGEN N.V. (the Netherlands), in May 2022, introduced a therascreen EGFR Plus RGQ PCR Kit, which is a new in vitro diagnostic test for the analysis of sensitive EGFR mutation.
- Guardant Health, Inc., in June 2021, introduced Guardant360 Response test that finds variations in circulating tumor DNA (ctDNA) levels.
- Hoffmann-La Roche Ltd. (Switzerland), in October 2020, gained United States FDA approval for the extended claims for cobas EGFR Mutation Test v2 to be deployed as a companion diagnostic for an extensive range of therapies to manage non-small cell lung cancer (NSCLC).
- Biocept, Inc., in March 2020, agreed with a California-based Independent Physician Association (IPA) to offer its Target Selector liquid assay services to patients and physicians in the network.
Key Companies Profiled:
- BIOCEPT, INC.
- Qiagen N.V.
- Trovagene, Inc
- Janssen Global Services, LLC
- MDxHealth SA
- Natera, Inc
- F. Hoffmann-La Roche Ltd
- Silicon Biosystems
- Pathway Genomics Corporation
- Sysmex Corporation
- Others
Key Segments Profiled in the Liquid Biopsy Industry Survey:
By Biomarker Type:
- CTCs (Circulating Tumour Cells)
- ctNA (Circulating tumor Nucleic Acids)
- Exosomes
By Sample Type:
- Blood Liquid Biopsy
- Urine Liquid Biopsy
- Other (Plasma, Saliva, CSF) Liquid Biopsy
By Application Type:
- Liquid Biopsy for Lung Cancer
- Liquid Biopsy for Gastrointestinal Cancer
- Liquid Biopsy for Prostate Cancer
- Liquid Biopsy for Breast Cancer
- Liquid Biopsy for Colorectal Cancer
- Liquid Biopsy for Leukemia
By Region:
- North America
- Latin America
- Western Europe
- Eastern Europe
- Asia Pacific Excluding Japan
- Japan
- Middle East and Africa
Obtain In-Depth Market Insights: Purchase Now to Access:
https://www.futuremarketinsights.com/checkout/1396
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube